Key Facts GPs Should Know About GLP-1 Analogs
Family Medicine Initiative
APRIL 9, 2024
In March 2024, FDA therefore approved semaglutide for secondary CVD prevention in overweight or obese adults. 4 Chronic Kidney Disease The FLOW trial randomized 3,534 patients with chronic kidney disease and type 2 diabetes and started treating them with s.c. over 40 months (ARR). semaglutide 2.4 mg or placebo for 52 weeks.
Let's personalize your content